About 2 results found for searched term "CY-09" (0.08 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M9263 | CY-09 | Pyroptosis |
| CY09 | ||
| CY-09 is a selective direct inhibitor of NLRP3 with anti-inflammatory and antidepressant activity, which inhibits inflammatory cytokine production and TRPA1 activation by inhibiting the activation of the NLRP3 inflammatory vesicle, thereby decreasing the intracellular Ca2+ level and reducing the pro-inflammatory polarization of macrophages, alleviating pain and injury in animals. In addition, CY-09 can inhibit pyroptosis. | ||
| M21654 | BTRX-335140 | Opioid Receptor |
| CYM-53093 | ||
| BTRX-335140 is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC50 values of 0.8 nM, 110 nM, and 6500 nM, respectively. Navacaprant endows with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rats. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
